Tanja Schmitz-Hübsch
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Tanja Schmitz-Hübsch has a total of 240 co-authors. Here are the top co-authors by number of shared publications:
Friedemann Paul
12 shared publications- Friedemann Paul
Max Delbrück Centrum für Molekulare Medizin und Charité – Universitätsmedizin Berlin
11 shared publications Alexander U. Brandt
Department of Neurology, University of California, Irvine, USA
6 shared publications- Alexander Ulrich Brandt
Experimental and Clinical Research Center, Max Delbrück Center for Molecular Medicine and Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt‐Universität zu Berlin Berlin Germany
6 shared publications Judith Bellmann-Strobl
Experimental and Clinical Research Center, Max Delbrück Center for Molecular Medicine, Charité – Universitätsmedizin Berlin, 13125 Berlin, Germany; Neuroscience Clinical Research Center, Charité – Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt-Universität zu Berlin, 10117 Berlin, Germany
5 shared publications- Daniel Kroneberg
Department of Neurology with Experimental Neurology, Charité‐Universitätsmedizin Berlin Corporate Member of Freie Universität Berlin and Humboldt‐Universität zu Berlin Berlin Germany
4 shared publications
Latest Publications
- Open Access
- 21 September 2026
- Published by Elsevier in SSRN Electronic Journal
Blood-based immune and proteomic signatures associated with paramagnetic rim lesions in relapsing-remitting multiple sclerosis
Paramagnetic rim lesions (PRLs) are imaging biomarkers of chronic active lesions in relapsing-remitting multiple sclerosis (RRMS), reflecting smoldering inflammation sustained by iron-laden microglia and macrophages at lesion edges. Their detection requires specialized susceptibility-sensitive MRI. Blood-based cellular and molecular correlates of PRL positivity remain largely unknown, limiting patient stratification beyond specialized imaging centers. We performed a multi-modal study integrating mass cytometry (CyTOF) immune profiling in PRL-positive (PRL⁺; n=13) and PRL-negative (PRL⁻; n=19) patients with RRMS, together with Olink Explore 3072 serum proteomics in a subset of 12 patients. PRL⁺ patients showed nominally higher frequencies of CD31⁺CD57⁺CD8⁺ cytotoxic effector T cells with a tissue-homing profile, TCR double-negative T cells, and a TCR Vα7.2⁺CCR5⁺ mucosal-associated invariant T (MAIT) cell phenotype, as well as an expanded classical monocyte subset. These populations showed PRL-dependent correlations with differentially expressed serum proteins, including PDP1, ADRA2A, SAT2, CASP1, SIRT1 and TGFBR1. This hypothesis-generating study identifies candidate blood-based correlates of chronic active lesion activity in RRMS, providing a basis for future biomarker studies and for therapeutic strategies targeting smoldering inflammation in pwMS.
- 21 September 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessBlood-based immune and proteomic signatures associated with paramagnetic rim lesions in relapsing-remitting multiple sclerosis
Paramagnetic rim lesions (PRLs) are imaging biomarkers of chronic active lesions in relapsing-remitting multiple sclerosis (RRMS), reflecting smoldering inflammation sustained by iron-laden microglia and macrophages at lesion edges. Their detection requires specialized susceptibility-sensitive MRI. Blood-based cellular and molecular correlates of PRL positivity remain largely unknown, limiting patient stratification beyond specialized imaging centers. We performed a multi-modal study integrating mass cytometry (CyTOF) immune profiling in PRL-positive (PRL⁺; n=13) and PRL-negative (PRL⁻; n=19) patients with RRMS, together with Olink Explore 3072 serum proteomics in a subset of 12 patients. PRL⁺ patients showed nominally higher frequencies of CD31⁺CD57⁺CD8⁺ cytotoxic effector T cells with a tissue-homing profile, TCR double-negative T cells, and a TCR Vα7.2⁺CCR5⁺ mucosal-associated invariant T (MAIT) cell phenotype, as well as an expanded classical monocyte subset. These populations showed PRL-dependent correlations with differentially expressed serum proteins, including PDP1, ADRA2A, SAT2, CASP1, SIRT1 and TGFBR1. This hypothesis-generating study identifies candidate blood-based correlates of chronic active lesion activity in RRMS, providing a basis for future biomarker studies and for therapeutic strategies targeting smoldering inflammation in pwMS.
- Open Access
Intrathecal antibodies cross-react with EBV BRRF2 and human antigens in multiple sclerosis
Intrathecal antibody synthesis is a hallmark of multiple sclerosis (MS). Although some intrathecally synthesized antibodies in MS are known to target viral antigens, the spectrum of their antigenic specificities remains incompletely defined. We combined proteome-wide antibody profiling by Phage ImmunoPrecipitation Sequencing (PhIP-Seq) with cross-compartment analytics (MICAR) to study intrathecal antibody synthesis at peptide resolution in paired CSF and serum samples from individuals with MS (n = 40) and non-MS controls (n = 83). While intrathecal antibody responses in MS were polyspecific and included reactivities to various viruses, we identified a subset of individuals with a convergent intrathecal antibody reactivity to a previously described motif within the Epstein-Barr virus (EBV) protein BRRF2 (BRRF2 408–415 ). This motif-directed response showed co-reactivity with multiple CNS-expressed human antigens. In an independent cohort of n = 909 individuals with MS and n = 311 controls, including individuals with NMOSD and MOGAD, serum antibodies to BRRF2 408–415 were detected in 8.36% of MS individuals and in 0.64% of non-MS controls, corresponding to an odds ratio for MS of 14.1 (95% CI: 4.4–86.04). Within MS individuals, BRRF2 408–415 seropositivity was associated with increased intrathecal IgG synthesis. Cross-reactivity of antibodies to BRRF2 408–415 with human targets, including TRIM71 and RTN2, was confirmed by competition ELISA and cell-based assays. Together, these data define an intrathecal EBV BRRF2-linked antibody signature with human target cross-reactivity in a subset of MS individuals. This signature identifies a highly specific serological marker in MS and may support future stratification of the heterogeneous MS spectrum.
Open AccessIntrathecal antibodies cross-react with EBV BRRF2 and human antigens in multiple sclerosis
Intrathecal antibody synthesis is a hallmark of multiple sclerosis (MS). Although some intrathecally synthesized antibodies in MS are known to target viral antigens, the spectrum of their antigenic specificities remains incompletely defined. We combined proteome-wide antibody profiling by Phage ImmunoPrecipitation Sequencing (PhIP-Seq) with cross-compartment analytics (MICAR) to study intrathecal antibody synthesis at peptide resolution in paired CSF and serum samples from individuals with MS (n = 40) and non-MS controls (n = 83). While intrathecal antibody responses in MS were polyspecific and included reactivities to various viruses, we identified a subset of individuals with a convergent intrathecal antibody reactivity to a previously described motif within the Epstein-Barr virus (EBV) protein BRRF2 (BRRF2 408–415 ). This motif-directed response showed co-reactivity with multiple CNS-expressed human antigens. In an independent cohort of n = 909 individuals with MS and n = 311 controls, including individuals with NMOSD and MOGAD, serum antibodies to BRRF2 408–415 were detected in 8.36% of MS individuals and in 0.64% of non-MS controls, corresponding to an odds ratio for MS of 14.1 (95% CI: 4.4–86.04). Within MS individuals, BRRF2 408–415 seropositivity was associated with increased intrathecal IgG synthesis. Cross-reactivity of antibodies to BRRF2 408–415 with human targets, including TRIM71 and RTN2, was confirmed by competition ELISA and cell-based assays. Together, these data define an intrathecal EBV BRRF2-linked antibody signature with human target cross-reactivity in a subset of MS individuals. This signature identifies a highly specific serological marker in MS and may support future stratification of the heterogeneous MS spectrum.
- Open Access
- 28 July 2026
- Published by Wiley in Brain and Behavior
- Vol. 16 (8) , e71612
Retinal Layer Thickness for Risk Stratification of Progression Independent of Relapse Activity in Relapsing‐Remitting Multiple Sclerosis
Background: Identifying people with relapsing‐remitting multiple sclerosis (pwRRMS) at risk of progression independent of relapse activity (PIRA) remains an unmet clinical need. Optical coherence tomography (OCT)‐derived measures of retinal neuroaxonal damage may provide prognostic value. This study aimed to evaluate whether peripapillary retinal nerve fiber layer (pRNFL) and ganglion cell‐inner plexiform layer (GCIP) thickness predict PIRA within a heterogenous group of pwRRMS. Methods: We retrospectively screened pwRRMS with ≥ 2 years relapse‐free follow‐up from prospective observational cohort studies in Berlin ( n = 74) and Munich ( n = 146). PIRA was defined as disability worsening, determined by method‐specific thresholds across multimodal assessments, sustained until end of follow‐up. Analyses were restricted to non‐optic neuritis eyes. Cox hazard models were used to assess the adjusted hazard (aHR) of PIRA with age‐adjusted pRNFL or GCIP Z ‐scores. Results: Out of 220 pwRRMS (age: 38.1 ± 9.9 years), 65 (29.5%) developed PIRA over a follow‐up of 2.9 [IQR: 1.6–4.1] years. No associations between OCT measures and PIRA were found within the overall study population or Munich cohort. In the Berlin cohort, thinner pRNFL predicted PIRA (aHR [95% CI] = 1.41 [1.03–1.92], p = 0.032), while GCIP did not (aHR [95% CI] = 1.38 [0.90–2.10], p = 0.140). Conclusions: OCT measurements do not predict the hazard of PIRA within a heterogeneous group of pwRRMS. However, they have potential prognostic value in early disease stages. Clinical characteristics might influence the association and require further investigation.
- 28 July 2026
- Published by Wiley in Brain and Behavior
- Vol. 16 (8) , e71612
Open AccessRetinal Layer Thickness for Risk Stratification of Progression Independent of Relapse Activity in Relapsing‐Remitting Multiple Sclerosis
Background: Identifying people with relapsing‐remitting multiple sclerosis (pwRRMS) at risk of progression independent of relapse activity (PIRA) remains an unmet clinical need. Optical coherence tomography (OCT)‐derived measures of retinal neuroaxonal damage may provide prognostic value. This study aimed to evaluate whether peripapillary retinal nerve fiber layer (pRNFL) and ganglion cell‐inner plexiform layer (GCIP) thickness predict PIRA within a heterogenous group of pwRRMS. Methods: We retrospectively screened pwRRMS with ≥ 2 years relapse‐free follow‐up from prospective observational cohort studies in Berlin ( n = 74) and Munich ( n = 146). PIRA was defined as disability worsening, determined by method‐specific thresholds across multimodal assessments, sustained until end of follow‐up. Analyses were restricted to non‐optic neuritis eyes. Cox hazard models were used to assess the adjusted hazard (aHR) of PIRA with age‐adjusted pRNFL or GCIP Z ‐scores. Results: Out of 220 pwRRMS (age: 38.1 ± 9.9 years), 65 (29.5%) developed PIRA over a follow‐up of 2.9 [IQR: 1.6–4.1] years. No associations between OCT measures and PIRA were found within the overall study population or Munich cohort. In the Berlin cohort, thinner pRNFL predicted PIRA (aHR [95% CI] = 1.41 [1.03–1.92], p = 0.032), while GCIP did not (aHR [95% CI] = 1.38 [0.90–2.10], p = 0.140). Conclusions: OCT measurements do not predict the hazard of PIRA within a heterogeneous group of pwRRMS. However, they have potential prognostic value in early disease stages. Clinical characteristics might influence the association and require further investigation.
- Open Access
- 28 July 2026
- Published by Wiley in Annals of Clinical and Translational Neurology
Evaluation of Dried Plasma Spot‐Based Quantification of Glial Fibrillary Acidic Protein as a Disease‐Associated Biomarker in Neuromyelitis Optica Spectrum Disorder
Objective: To evaluate the diagnostic accuracy of glial fibrillary acidic protein (GFAP) measured in dried plasma spots versus conventional plasma‐ and serum‐GFAP testing for assessment of disease severity in aquaporin‐4 immunoglobulin G–positive neuromyelitis optica spectrum disorder (AQP4‐IgG + NMOSD). Methods: A neuroimmunological prospective cohort of remission samples from 70 participants with the diagnoses AQP4‐IgG + NMOSD ( n = 19), myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD; n = 9), relapsing–remitting multiple sclerosis (RRMS; n = 28) and healthy controls (HC; n = 14) from a single center were included. GFAP concentrations were measured in frozen and thawed plasma and paired dried plasma spot (DPS) samples using an ultrasensitive proximity ligation–based assay (nucleic acid–linked immuno‐sandwich assay; NULISA). In NMOSD, GFAP was additionally quantified in paired serum samples using a single‐molecule array (Simoa) assay as a reference. Cross‐matrix correlations, diagnostic performance, and associations with neurological disability were evaluated. Results: GFAP concentrations measured by NULISA correlated strongly between plasma and DPS samples across diagnostic groups and healthy controls. In NMOSD, plasma GFAP measured by NULISA showed strong concordance with serum GFAP quantified by Simoa. DPS‐derived and plasma‐derived GFAP demonstrated good diagnostic accuracy for AQP4‐IgG + NMOSD and was significantly associated with neurological disability as measured by the Expanded Disability Status Scale (EDSS). Group‐wise comparisons across plasma and DPS showed retained elevation of GFAP in AQP4‐IgG + NMOSD compared with the other diagnostic groups and healthy controls. Interpretation: GFAP quantification using the NULISA platform is feasible in plasma and DPS samples and enables reliable biomarker assessment in a potentially remote‐compatible setting. DPS‐derived GFAP measurements retained meaningful information on disability in NMOSD and may provide an analytical framework for future studies evaluating minimally invasive capillary or self‐sampling approaches.
- 28 July 2026
- Published by Wiley in Annals of Clinical and Translational Neurology
Open AccessEvaluation of Dried Plasma Spot‐Based Quantification of Glial Fibrillary Acidic Protein as a Disease‐Associated Biomarker in Neuromyelitis Optica Spectrum Disorder
Objective: To evaluate the diagnostic accuracy of glial fibrillary acidic protein (GFAP) measured in dried plasma spots versus conventional plasma‐ and serum‐GFAP testing for assessment of disease severity in aquaporin‐4 immunoglobulin G–positive neuromyelitis optica spectrum disorder (AQP4‐IgG + NMOSD). Methods: A neuroimmunological prospective cohort of remission samples from 70 participants with the diagnoses AQP4‐IgG + NMOSD ( n = 19), myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD; n = 9), relapsing–remitting multiple sclerosis (RRMS; n = 28) and healthy controls (HC; n = 14) from a single center were included. GFAP concentrations were measured in frozen and thawed plasma and paired dried plasma spot (DPS) samples using an ultrasensitive proximity ligation–based assay (nucleic acid–linked immuno‐sandwich assay; NULISA). In NMOSD, GFAP was additionally quantified in paired serum samples using a single‐molecule array (Simoa) assay as a reference. Cross‐matrix correlations, diagnostic performance, and associations with neurological disability were evaluated. Results: GFAP concentrations measured by NULISA correlated strongly between plasma and DPS samples across diagnostic groups and healthy controls. In NMOSD, plasma GFAP measured by NULISA showed strong concordance with serum GFAP quantified by Simoa. DPS‐derived and plasma‐derived GFAP demonstrated good diagnostic accuracy for AQP4‐IgG + NMOSD and was significantly associated with neurological disability as measured by the Expanded Disability Status Scale (EDSS). Group‐wise comparisons across plasma and DPS showed retained elevation of GFAP in AQP4‐IgG + NMOSD compared with the other diagnostic groups and healthy controls. Interpretation: GFAP quantification using the NULISA platform is feasible in plasma and DPS samples and enables reliable biomarker assessment in a potentially remote‐compatible setting. DPS‐derived GFAP measurements retained meaningful information on disability in NMOSD and may provide an analytical framework for future studies evaluating minimally invasive capillary or self‐sampling approaches.
- Open Access
- 12 November 2025
- Published by Wiley in European Journal of Neurology
- Vol. 32 (11) , e70375
Serum Neurofilament Light Is Associated With Future Disease Activity in Clinically Isolated Syndrome and Early Multiple Sclerosis Only After Non‐Optic Neuritis Onset
Background: We compared the prognostic value of serum neurofilament light chain (sNFL) and glial fibrillary acidic protein (sGFAP) for clinical and radiologic disease activity among patients with clinically isolated syndrome or early multiple sclerosis (MS) with optic neuritis (pwON) and non‐optic neuritis (pwNON) as the first manifestation. Methods: Patients within 7 months (pwON and pwNON) from disease onset and patients with MS with a disease duration longer than 12 months (pwMS) as controls were included. sNFL and sGFAP were analyzed at baseline and at follow‐ups using SIMOA technology. Linear mixed models and Cox regression analyses were applied. Results: We included 165 samples of 86 patients (18 pwON, 46 pwNON, 21 pwMS). Median follow‐up time was 80 months. Mean sNFL z scores were higher in pwNON (1.06) than pwON (0.53) and pwMS (0.94). In pwNON, but not pwON, higher sNFL z scores were associated with an elevated risk for a subsequent attack (pwNON: HR 1.63 [95% CI 1.12 to 2.27], p = 0.005; pwON: HR 0.80 [95% CI 0.51–2.27], p = 0.318) and new MRI T2 lesions (pwNON: HR 1.66 [95% CI 1.31 to 2.11], p < 0.001; pwON: HR 1.16 [95% CI 0.82 to 1.63], p = 0.404). sGFAP z scores were associated with a lower risk of a subsequent attack in pwON (HR 0.34 [95% CI 0.12 to 0.98], p = 0.047). Conclusion: sNFL but not sGFAP predicted future clinical and MRI disease activity only in pwNON, potentially suggesting that the prognostic value of sNFL may depend on the type of the first manifestation.
- 12 November 2025
- Published by Wiley in European Journal of Neurology
- Vol. 32 (11) , e70375
Open AccessSerum Neurofilament Light Is Associated With Future Disease Activity in Clinically Isolated Syndrome and Early Multiple Sclerosis Only After Non‐Optic Neuritis Onset
Background: We compared the prognostic value of serum neurofilament light chain (sNFL) and glial fibrillary acidic protein (sGFAP) for clinical and radiologic disease activity among patients with clinically isolated syndrome or early multiple sclerosis (MS) with optic neuritis (pwON) and non‐optic neuritis (pwNON) as the first manifestation. Methods: Patients within 7 months (pwON and pwNON) from disease onset and patients with MS with a disease duration longer than 12 months (pwMS) as controls were included. sNFL and sGFAP were analyzed at baseline and at follow‐ups using SIMOA technology. Linear mixed models and Cox regression analyses were applied. Results: We included 165 samples of 86 patients (18 pwON, 46 pwNON, 21 pwMS). Median follow‐up time was 80 months. Mean sNFL z scores were higher in pwNON (1.06) than pwON (0.53) and pwMS (0.94). In pwNON, but not pwON, higher sNFL z scores were associated with an elevated risk for a subsequent attack (pwNON: HR 1.63 [95% CI 1.12 to 2.27], p = 0.005; pwON: HR 0.80 [95% CI 0.51–2.27], p = 0.318) and new MRI T2 lesions (pwNON: HR 1.66 [95% CI 1.31 to 2.11], p < 0.001; pwON: HR 1.16 [95% CI 0.82 to 1.63], p = 0.404). sGFAP z scores were associated with a lower risk of a subsequent attack in pwON (HR 0.34 [95% CI 0.12 to 0.98], p = 0.047). Conclusion: sNFL but not sGFAP predicted future clinical and MRI disease activity only in pwNON, potentially suggesting that the prognostic value of sNFL may depend on the type of the first manifestation.
- Open Access
- 12 June 2024
- Published by Open Exploration Publishing
- Vol. 4, 273-287
Cognitive-motor interference in multiple sclerosis and healthy controls: results from single, dual, and triple task posturography
Aim: This article is based on our previous research, which was presented as a poster at the ECTRIMS Congress 2018 and published as a conference abstract (https://www.professionalabstracts.com/ectrims2018/iplanner/#/presentation/1698). Cognitive-motor interference (CMI) has been observed in both healthy controls (HC) and persons with multiple sclerosis (pwMS), but limited and contradictory data is making it difficult to assess the impact of motor and cognitive functioning levels on CMI. The aim of this study was to investigate CMI in pwMS and HC by means of a dual task postural paradigm, to compare them between groups and to analyse the influence of motor and cognitive functioning levels assessed with complementary instruments on observed CMI. Methods: The dual task posturography paradigm serves to quantify the impact of a cognitive (i.e., performing serial subtractions), a motor challenge (closing eyes), or both challenges combined (triple task) on body sway during standing in an upright position feet closed. The data analysed were acquired in one interventional and four observational studies and selected based on predefined criteria and by systematic quality control. A total of 113 pwMS and 42 HC were selected for analysis. Results: Comparable changes in motor and cognitive performance due to cognitive or combined cognitive-motor challenges were observed in both HC and pwMS. Combining both tasks did not result in further changes in motor performance but resulted in a decrease in cognitive performance. This reduction in cognitive performance with an additional motor challenge correlated with lower levels of cognitive and motor functioning in pwMS. Unexpectedly, an increase in body sway due to a cognitive or combined cognitive-motor challenges was primarily observed in pwMS and HC with better cognitive and motor functioning. Conclusions: The results suggest that dual-task effects are not disease-specific but rather reflect individually different adaptation strategies depending on the specific motor and cognitive functioning levels.
- 12 June 2024
- Published by Open Exploration Publishing
- Vol. 4, 273-287
Open AccessCognitive-motor interference in multiple sclerosis and healthy controls: results from single, dual, and triple task posturography
Aim: This article is based on our previous research, which was presented as a poster at the ECTRIMS Congress 2018 and published as a conference abstract (https://www.professionalabstracts.com/ectrims2018/iplanner/#/presentation/1698). Cognitive-motor interference (CMI) has been observed in both healthy controls (HC) and persons with multiple sclerosis (pwMS), but limited and contradictory data is making it difficult to assess the impact of motor and cognitive functioning levels on CMI. The aim of this study was to investigate CMI in pwMS and HC by means of a dual task postural paradigm, to compare them between groups and to analyse the influence of motor and cognitive functioning levels assessed with complementary instruments on observed CMI. Methods: The dual task posturography paradigm serves to quantify the impact of a cognitive (i.e., performing serial subtractions), a motor challenge (closing eyes), or both challenges combined (triple task) on body sway during standing in an upright position feet closed. The data analysed were acquired in one interventional and four observational studies and selected based on predefined criteria and by systematic quality control. A total of 113 pwMS and 42 HC were selected for analysis. Results: Comparable changes in motor and cognitive performance due to cognitive or combined cognitive-motor challenges were observed in both HC and pwMS. Combining both tasks did not result in further changes in motor performance but resulted in a decrease in cognitive performance. This reduction in cognitive performance with an additional motor challenge correlated with lower levels of cognitive and motor functioning in pwMS. Unexpectedly, an increase in body sway due to a cognitive or combined cognitive-motor challenges was primarily observed in pwMS and HC with better cognitive and motor functioning. Conclusions: The results suggest that dual-task effects are not disease-specific but rather reflect individually different adaptation strategies depending on the specific motor and cognitive functioning levels.
- Open Access
Gait Variability as a Potential Motor Marker of Cerebellar Disease—Relationship between Variability of Stride, Arm Swing and Trunk Movements, and Walking Speed
Excessive stride variability is a characteristic feature of cerebellar ataxias, even in pre-ataxic or prodromal disease stages. This study explores the relation of variability of arm swing and trunk deflection in relationship to stride length and gait speed in previously described cohorts of cerebellar disease and healthy elderly: we examined 10 patients with spinocerebellar ataxia type 14 (SCA), 12 patients with essential tremor (ET), and 67 healthy elderly (HE). Using inertial sensors, recordings of gait performance were conducted at different subjective walking speeds to delineate gait parameters and respective coefficients of variability (CoV). Comparisons across cohorts and walking speed categories revealed slower stride velocities in SCA and ET patients compared to HE, which was paralleled by reduced arm swing range of motion (RoM), peak velocity, and increased CoV of stride length, while no group differences were found for trunk deflections and their variability. Larger arm swing RoM, peak velocity, and stride length were predicted by higher gait velocity in all cohorts. Lower gait velocity predicted higher CoV values of trunk sagittal and horizontal deflections, as well as arm swing and stride length in ET and SCA patients, but not in HE. These findings highlight the role of arm movements in ataxic gait and the impact of gait velocity on variability, which are essential for defining disease manifestation and disease-related changes in longitudinal observations.
Open AccessGait Variability as a Potential Motor Marker of Cerebellar Disease—Relationship between Variability of Stride, Arm Swing and Trunk Movements, and Walking Speed
Excessive stride variability is a characteristic feature of cerebellar ataxias, even in pre-ataxic or prodromal disease stages. This study explores the relation of variability of arm swing and trunk deflection in relationship to stride length and gait speed in previously described cohorts of cerebellar disease and healthy elderly: we examined 10 patients with spinocerebellar ataxia type 14 (SCA), 12 patients with essential tremor (ET), and 67 healthy elderly (HE). Using inertial sensors, recordings of gait performance were conducted at different subjective walking speeds to delineate gait parameters and respective coefficients of variability (CoV). Comparisons across cohorts and walking speed categories revealed slower stride velocities in SCA and ET patients compared to HE, which was paralleled by reduced arm swing range of motion (RoM), peak velocity, and increased CoV of stride length, while no group differences were found for trunk deflections and their variability. Larger arm swing RoM, peak velocity, and stride length were predicted by higher gait velocity in all cohorts. Lower gait velocity predicted higher CoV values of trunk sagittal and horizontal deflections, as well as arm swing and stride length in ET and SCA patients, but not in HE. These findings highlight the role of arm movements in ataxic gait and the impact of gait velocity on variability, which are essential for defining disease manifestation and disease-related changes in longitudinal observations.
- Open Access
- 30 October 2023
- Published by Wiley in Annals of Clinical and Translational Neurology
- Vol. 11 (1) , 45-56
Interactions of optic radiation lesions with retinal and brain atrophy in early multiple sclerosis
Objective: Retrograde trans‐synaptic neuroaxonal degeneration is considered a key pathological factor of subclinical retinal neuroaxonal damage in multiple sclerosis (MS). We aim to evaluate the longitudinal association of optic radiation (OR) lesion activity with retinal neuroaxonal damage and its role in correlations between retinal and brain atrophy in people with clinically isolated syndrome and early MS (pweMS).Methods: Eighty‐five pweMS were retrospectively screened from a prospective cohort (Berlin CIS cohort). Participants underwent 3T magnetic resonance imaging (MRI) for OR lesion volume and brain atrophy measurements and optical coherence tomography (OCT) for retinal layer thickness measurements. All pweMS were followed with serial OCT and MRI over a median follow‐up of 2.9 (interquartile range: 2.6–3.4) years. Eyes with a history of optic neuritis prior to study enrollment were excluded. Linear mixed models were used to analyze the association of retinal layer thinning with changes in OR lesion volume and brain atrophy.Results: Macular ganglion cell‐inner plexiform layer (GCIPL) thinning was more pronounced in pweMS with OR lesion volume increase during follow‐up compared to those without (Difference: −0.82 μm [95% CI:‐1.49 to −0.15], p = 0.018). Furthermore, GCIPL thinning correlated with both OR lesion volume increase (β [95% CI] = −0.27 [−0.50 to −0.03], p = 0.028) and brain atrophy (β [95% CI] = 0.47 [0.25 to 0.70], p < 0.001). Correlations of GCIPL changes with brain atrophy did not differ between pweMS with or without OR lesion increase ( = 5.92e−7, p = 0.762).Interpretation: Faster GCIPL thinning rate is associated with increased OR lesion load. Our results support the value of GCIPL as a sensitive biomarker reflecting both posterior visual pathway pathology and global brain neurodegeneration.
- 30 October 2023
- Published by Wiley in Annals of Clinical and Translational Neurology
- Vol. 11 (1) , 45-56
Open AccessInteractions of optic radiation lesions with retinal and brain atrophy in early multiple sclerosis
Objective: Retrograde trans‐synaptic neuroaxonal degeneration is considered a key pathological factor of subclinical retinal neuroaxonal damage in multiple sclerosis (MS). We aim to evaluate the longitudinal association of optic radiation (OR) lesion activity with retinal neuroaxonal damage and its role in correlations between retinal and brain atrophy in people with clinically isolated syndrome and early MS (pweMS).Methods: Eighty‐five pweMS were retrospectively screened from a prospective cohort (Berlin CIS cohort). Participants underwent 3T magnetic resonance imaging (MRI) for OR lesion volume and brain atrophy measurements and optical coherence tomography (OCT) for retinal layer thickness measurements. All pweMS were followed with serial OCT and MRI over a median follow‐up of 2.9 (interquartile range: 2.6–3.4) years. Eyes with a history of optic neuritis prior to study enrollment were excluded. Linear mixed models were used to analyze the association of retinal layer thinning with changes in OR lesion volume and brain atrophy.Results: Macular ganglion cell‐inner plexiform layer (GCIPL) thinning was more pronounced in pweMS with OR lesion volume increase during follow‐up compared to those without (Difference: −0.82 μm [95% CI:‐1.49 to −0.15], p = 0.018). Furthermore, GCIPL thinning correlated with both OR lesion volume increase (β [95% CI] = −0.27 [−0.50 to −0.03], p = 0.028) and brain atrophy (β [95% CI] = 0.47 [0.25 to 0.70], p < 0.001). Correlations of GCIPL changes with brain atrophy did not differ between pweMS with or without OR lesion increase ( = 5.92e−7, p = 0.762).Interpretation: Faster GCIPL thinning rate is associated with increased OR lesion load. Our results support the value of GCIPL as a sensitive biomarker reflecting both posterior visual pathway pathology and global brain neurodegeneration.
- Open Access
- 10 October 2023
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 14, 1258635
Progression events defined by home-based assessment of motor function in multiple sclerosis: protocol of a prospective study
Background: This study relates to emerging concepts of appropriate trial designs to evaluate effects of intervention on the accumulation of irreversible disability in multiple sclerosis (MS). Major starting points of our study are the known limitations of current definitions of disability progression by rater-based clinical assessment and the high relevance of gait and balance dysfunctions in MS. The study aims to explore a novel definition of disease progression using repeated instrumental assessment of relevant motor functions performed by patients in their home setting.Methods: The study is a prospective single-center observational cohort study with the primary outcome acquired by participants themselves, a home-based assessment of motor functions based on an RGB-Depth (RGB-D) camera, a camera that provides both depth (D) and color (RGB) data. Participants are instructed to perform and record a set of simple motor tasks twice a day over a one-week period every 6 months. Assessments are complemented by a set of questionnaires. Annual research grade assessments are acquired at dedicated study visits and include clinical ratings as well as structural imaging (MRI and optical coherence tomography). In addition, clinical data from routine visits is provided semiannually by treating neurologists. The observation period is 24 months for the primary endpoint with an additional clinical assessment at 27 month to confirm progression defined by the Expanded Disability Status Scale (EDSS). Secondary analyses aim to explore the time course of changes in motor parameters and performance of the novel definition against different alternative definitions of progression in MS. The study was registered at Deutsches Register für Klinische Studien (DRKS00027042).Discussion: The study design presented here investigates disease progression defined by marker-less home-based assessment of motor functions against 3-month confirmed disease progression (3 m-CDP) defined by the EDSS. The technical approach was chosen due to previous experience in lab-based settings. The observation time per participant of 24, respectively, 27 months is commonly conceived as the lower limit needed to study disability progression. Defining a valid digital motor outcome for disease progression in MS may help to reduce observation times in clinical trials and add confidence to the detection of progression events in MS.
- 10 October 2023
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 14, 1258635
Open AccessProgression events defined by home-based assessment of motor function in multiple sclerosis: protocol of a prospective study
Background: This study relates to emerging concepts of appropriate trial designs to evaluate effects of intervention on the accumulation of irreversible disability in multiple sclerosis (MS). Major starting points of our study are the known limitations of current definitions of disability progression by rater-based clinical assessment and the high relevance of gait and balance dysfunctions in MS. The study aims to explore a novel definition of disease progression using repeated instrumental assessment of relevant motor functions performed by patients in their home setting.Methods: The study is a prospective single-center observational cohort study with the primary outcome acquired by participants themselves, a home-based assessment of motor functions based on an RGB-Depth (RGB-D) camera, a camera that provides both depth (D) and color (RGB) data. Participants are instructed to perform and record a set of simple motor tasks twice a day over a one-week period every 6 months. Assessments are complemented by a set of questionnaires. Annual research grade assessments are acquired at dedicated study visits and include clinical ratings as well as structural imaging (MRI and optical coherence tomography). In addition, clinical data from routine visits is provided semiannually by treating neurologists. The observation period is 24 months for the primary endpoint with an additional clinical assessment at 27 month to confirm progression defined by the Expanded Disability Status Scale (EDSS). Secondary analyses aim to explore the time course of changes in motor parameters and performance of the novel definition against different alternative definitions of progression in MS. The study was registered at Deutsches Register für Klinische Studien (DRKS00027042).Discussion: The study design presented here investigates disease progression defined by marker-less home-based assessment of motor functions against 3-month confirmed disease progression (3 m-CDP) defined by the EDSS. The technical approach was chosen due to previous experience in lab-based settings. The observation time per participant of 24, respectively, 27 months is commonly conceived as the lower limit needed to study disability progression. Defining a valid digital motor outcome for disease progression in MS may help to reduce observation times in clinical trials and add confidence to the detection of progression events in MS.
- Open Access
- 9 October 2023
- Published by Springer Nature in Health and Quality of Life Outcomes
- Vol. 21 (1) , 1-12
Translation and validation of the multiple sclerosis walking scale 12 for the German population – the MSWS-12/D
Background: Gait impairment is a relevant problem in persons with multiple sclerosis (pwMS). The Multiple Sclerosis Walking Scale 12 (MSWS-12) is a valid Patient Reported Outcome Measure (PROM) to evaluate walking ability in pwMS. The aim of this study was to provide a linguistically valid translation of MSWS-12 into German language (MSWS-12/D) and to evaluate its psychometric properties. Methods: The MSWS-12 was translated in a process modified from guidelines for the cross-cultural adaption of PROMs, and a pre-test was applied in a small sample of 20 pwMS to evaluate comprehensibility and acceptance. Psychometric properties (floor and ceiling effects, internal consistency, construct validity) were then assessed in 124 pwMS seen at academic MS centers. Construct validity was evaluated against Expanded Disability Status Scale (EDSS) and maximum gait speed in the Timed 25-Foot Walk (T25FW). Results: Although the sample covered a wide spectrum of symptom severity, the majority had rather low levels of disability (EDSS median 2.0) and 6.5% scored EDSS of 0. In this sample, MSWS-12/D showed floor effects (36% with score 0) and for internal consistency, a Cronbach’s alpha of 0.98 was calculated. MSWS-12/D score showed a relevant correlation to EDSS (ρ = 0.73) and T25FW speed (r=-0.72). Conclusion: We provide MSWS-12/D as a linguistically valid German version of MSWS-12. Psychometric properties (acceptance, floor and ceiling effects, internal consistency and construct validity) in pwMS were similar to those described for the original version. This indicates that MSWS-12/D can be applied as equivalent to the original version in German speaking pwMS. Results support the relevance of PROMs to capture patient perception of walking ability in addition to performance-based assessments such as maximum walking speed or maximum walking distance.
- 9 October 2023
- Published by Springer Nature in Health and Quality of Life Outcomes
- Vol. 21 (1) , 1-12
Open AccessTranslation and validation of the multiple sclerosis walking scale 12 for the German population – the MSWS-12/D
Background: Gait impairment is a relevant problem in persons with multiple sclerosis (pwMS). The Multiple Sclerosis Walking Scale 12 (MSWS-12) is a valid Patient Reported Outcome Measure (PROM) to evaluate walking ability in pwMS. The aim of this study was to provide a linguistically valid translation of MSWS-12 into German language (MSWS-12/D) and to evaluate its psychometric properties. Methods: The MSWS-12 was translated in a process modified from guidelines for the cross-cultural adaption of PROMs, and a pre-test was applied in a small sample of 20 pwMS to evaluate comprehensibility and acceptance. Psychometric properties (floor and ceiling effects, internal consistency, construct validity) were then assessed in 124 pwMS seen at academic MS centers. Construct validity was evaluated against Expanded Disability Status Scale (EDSS) and maximum gait speed in the Timed 25-Foot Walk (T25FW). Results: Although the sample covered a wide spectrum of symptom severity, the majority had rather low levels of disability (EDSS median 2.0) and 6.5% scored EDSS of 0. In this sample, MSWS-12/D showed floor effects (36% with score 0) and for internal consistency, a Cronbach’s alpha of 0.98 was calculated. MSWS-12/D score showed a relevant correlation to EDSS (ρ = 0.73) and T25FW speed (r=-0.72). Conclusion: We provide MSWS-12/D as a linguistically valid German version of MSWS-12. Psychometric properties (acceptance, floor and ceiling effects, internal consistency and construct validity) in pwMS were similar to those described for the original version. This indicates that MSWS-12/D can be applied as equivalent to the original version in German speaking pwMS. Results support the relevance of PROMs to capture patient perception of walking ability in addition to performance-based assessments such as maximum walking speed or maximum walking distance.